| payload |
{"created_at":"2026-04-16T10:15:40.769 {"created_at":"2026-04-16T10:15:40.769768+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:9f3c2fba5d6a1344","evidence_event_ids":["evt_446e673565bb"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/why-beaten-down-cannabis-giant-table-pounding-buy","as_of":"2026-04-16T10:15:40.769768+00:00","canonical_url":"https://www.fool.com/investing/2026/04/16/why-this-beaten-down-cannabis-giant-is-a-table-pou/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/why-beaten-down-cannabis-giant-table-pounding-buy","article_chars":4558,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_7c6da4aa7d100dd0","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/16/why-this-beaten-down-cannabis-giant-is-a-table-pou/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-16T10:17:53.940740+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsGreen Thumb Industries' financials are strong with growing revenue and earnings and plenty of cash.","fetched_title":"Why This Beaten-Down Cannabis Giant is a Table-Pounding Buy | Nasdaq","final_url":"https://www.nasdaq.com/articles/why-beaten-down-cannabis-giant-table-pounding-buy","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/why-beaten-down-cannabis-giant-table-pounding-buy","source_event_id":"evt_446e673565bb","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"c7f7af1613481636","kind":"unusual_volume","published_at":"2026-04-16T09:04:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.74,"dates_mentioned":["December 2025","early 2021","April 2026","April 16, 2026","April (year not specified)"],"entities":[{"asset_class":"equity","name":"Green Thumb Industries","relevance":"high","symbol":"GTBIF","type":"company"},{"asset_class":"equity","name":"S&P Global","relevance":"medium","symbol":"SPGI","type":"company"},{"asset_class":"person","name":"Ben Kovler","relevance":"medium","symbol":"","type":"person"},{"asset_class":"person","name":"Donald Trump","relevance":"low","symbol":"","type":"person"},{"asset_class":"government","name":"U.S. Attorney General","relevance":"low","symbol":"","type":"government_body"}],"event_type":"regulation","information_gaps":["The signal type is discovery_unusual_volume_delta, but the provided text contains no volume ratio, baseline volume, or confirmation details about unusual trading volume.","The article does not provide the ticker in a standardized form beyond OTC: GTBIF; it does not explicitly state the exchange listing for the volume context.","The catalyst is described as an executive order directing expedited rescheduling; the article does not confirm that rescheduling to Schedule III has been finalized.","No explicit evidence is provided that the unusual volume (if any) is confirmed by news; the text only discusses financials and the rescheduling catalyst."],"key_facts":["The article states Green Thumb generated $1.2 billion in revenue for 2025 and earnings of $114 million last year.","It states Q4 revenue rose 5.7% year over year to $311.1 million and net income was $83.2 million.","It states Green Thumb generated cash flow from operations of roughly $295 million in 2025.","It states Green Thumb had cash of $274.3 million at the end of 2025.","It states the company increased its existing syndicated credit facility by $50 million.","It states President Trump signed an executive order in December 2025 directing the U.S. Attorney General to expedite rescheduling of cannabis to Schedule III.","The article claims Schedule III rescheduling would effectively lift IRS Section 280E restrictions on companies selling Schedule I or II drugs, allowing ordinary business expense deductions.","It states eight analysts surveyed by S&P Global in April rated the stock a buy.","It states the consensus 12-month price target implies roughly 169% upside."],"numeric_claims":[{"label":"Revenue (2025)","value":"$1.2 billion"},{"label":"Earnings (last year)","value":"$114 million"},{"label":"Q4 revenue (YoY)","value":"5.7%"},{"label":"Q4 revenue","value":"$311.1 million"},{"label":"Q4 net income","value":"$83.2 million"},{"label":"Cash flow from operations (2025)","value":"~$295 million"},{"label":"Cash position (end of 2025)","value":"$274.3 million"},{"label":"Credit facility increase","value":"$50 million"},{"label":"Analysts rated buy","value":"8"},{"label":"Implied 12-month upside","value":"~169%"}],"primary_claim":"Green Thumb Industries has strong financial results and an upcoming catalyst from the December 2025 executive order directing marijuana rescheduling to Schedule III, which could lift earnings by removing IRS Section 280E restrictions.","relevance_score":0.62,"sentiment":"positive","source_quality":"high","summary":"The article argues Green Thumb Industries is financially strong and has an upcoming catalyst tied to potential U.S. marijuana rescheduling, which the author expects could improve earnings. It also cites analyst buy ratings and a consensus 12-month upside estimate.","topics":["cannabis","marijuana rescheduling","Schedule III","IRS Section 280E","analyst price targets","financial performance","cash flow","balance sheet","credit facility"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsGreen Thumb Industries' financials are strong with growing revenue and earnings and plenty of cash.","tickers":[],"title":"Why This Beaten-Down Cannabis Giant is a Table-Pounding Buy","url":"https://www.fool.com/investing/2026/04/16/why-this-beaten-down-cannabis-giant-is-a-table-pou/"}}... |